METRNL mitigates oxidative stress and inflammatory drawbacks in ovalbumin/lipopolysaccharide-induced allergic airway diseases via the IKK/IκB/NF-κB signaling pathway.

This study aimed to examine the potential impacts of METRNL as an antioxidant and anti-inflammatory through IκB kinase/inhibitor of nuclear factor-kappa B/nuclear factor-kappa-light-chain signaling pathway on many biomarkers and lung structure in rats with bronchial asthma induced by ovalbumin/lipopolysaccharide (OVA/LPS). Forty rats were randomly divided into four equal groups: control group, vehicle group, diseased (OVA/LPS) group OVA 2.5 ml/kg intratracheal installation/LPS 1.5 mg/kg intraperitoneally, and treated (OVA/LPS + METRNL) group, METRNL at a dose of 2 mg/rat/day IV. After 4 weeks, plasma and lung tissues were analyzed to assess oxidative stress inflammatory markers. Additionally, a histological assessment was conducted on lung tissues. Bronchial asthma was confirmed when increased levels of total serum IgE, total cell count, neutrophils, eosinophils, macrophages, and lymphocyte counts in the BAL fluid were observed. Moreover, OVA/LPS resulted in a reduction in levels of superoxide dismutase (SOD) while raising levels of malondialdehyde (MDA). Furthermore, it elevated concentrations of plasma inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin 17 (IL-17), and transforming growth factor beta (TGF-β). The protective effects of METRNL were analyzed. The observed impacts are believed to result from the drug's anti-inflammatory and antioxidant properties and its action on the IKK/IκB/NF-κB signaling pathway. This investigation indicates that METRNL treatment positively improved rats' biochemical and histological aspects of OVA/LPS-induced airway allergic inflammation.